Story perspectives

Tempus AI Posts 89.6% Growth, Boosts Revenue Guidance

8/8/2025

27 4

Summary

Story summary

Tempus AI achieved Q2 2025 revenue of $314.6 million, marking an impressive 89.6% year-over-year growth.
The company reduced its EPS loss to $0.22, outperforming the anticipated $0.25 loss.
Genomics revenue soared 115.3% to $241.8 million, fueled by higher testing volumes.
Full-year revenue guidance was increased to $1.26 billion, reflecting robust growth prospects.
Tempus AI is advancing AI-driven healthcare solutions, strengthening its competitive edge.

History

Historical Context

The Precision Medicine Initiative, launched by President Obama in 2015, aimed to personalize healthcare through advanced genomic testing. By Q2 2025, Tempus AI reported an 89.6% revenue growth, reaching $314.6 million, reflecting the rising demand for AI-driven healthcare solutions. This trend underscores the transformative potential of AI in diagnostics and treatment, shaping the future of medical practices.

1 of 2

Story summary

Tempus AI achieved Q2 2025 revenue of $314.6 million, marking an impressive 89.6% year-over-year growth.
The company reduced its EPS loss to $0.22, outperforming the anticipated $0.25 loss.
Genomics revenue soared 115.3% to $241.8 million, fueled by higher testing volumes.
Full-year revenue guidance was increased to $1.26 billion, reflecting robust growth prospects.
Tempus AI is advancing AI-driven healthcare solutions, strengthening its competitive edge.

1 / 2